👁️ Around 12 million people worldwide risk losing their sight to corneal disease, and most can't get treatment because there simply aren't enough donor corneas to go around. Now a Japanese startup is launching the world's first clinical trial to grow replacement corneas from iPS cells, potentially ending the global donor shortage for good.

The Global Crisis: Corneal Blindness and the Donor Shortage

The cornea is the transparent outer layer of the eye that focuses incoming light. When it becomes damaged or clouded, the consequences can range from severely impaired vision to total blindness.

According to the World Health Organization, corneal opacity is the 4th leading cause of blindness globally. Research published in the journal Ophthalmology estimates that approximately 5.5 million people are bilaterally blind or severely vision-impaired from corneal diseases, with an additional 6.2 million blind in one eye, for a total of nearly 12 million affected individuals.

The standard treatment has long been corneal transplantation using tissue from deceased donors. But globally, there is a chronic shortage of donor corneas. In many developing countries where corneal blindness is most prevalent, eye banking infrastructure barely exists. Even in developed nations like Japan, demand for donor corneas consistently exceeds supply.

What Reimei Just Launched, and Why It Matters

In February 2026, Reimei Corporation, an Osaka University spinoff, announced the launch of a corporate clinical trial for an "allogeneic iPS cell-derived corneal epithelial cell sheet" (development code: REM-01). This is the world's first corporate-phase clinical trial of its kind, designed to pursue full regulatory approval.

Let's break down the key terms:

iPS cells: Discovered in 2006 by Kyoto University's Professor Shinya Yamanaka (who received the Nobel Prize in 2012 for this work), induced pluripotent stem cells are created by reprogramming ordinary cells (such as skin cells) back into a "blank slate" state, from which they can be guided into becoming virtually any type of cell in the body.

"Allogeneic" (donor-derived): Rather than making iPS cells from each individual patient, REM-01 uses cells derived from a donor. This is a game-changer because it allows mass production — cell sheets can be manufactured in advance, cryopreserved (frozen), and stored on the shelf, ready for use when patients need them. This dramatically cuts costs and wait times compared to patient-specific (autologous) approaches.

The SEAM Method: Developed by Professor Kohji Nishida at Osaka University, SEAM (Self-formed Ectodermal Autonomous Multi-zone) is an innovative technique that coaxes iPS cells into forming structures that mirror natural eye development. From a single culture dish, the method simultaneously generates cells resembling the cornea, lens, and retina — essentially recreating eye formation in miniature. Corneal epithelial cells are then isolated from this structure to build transplantable cell sheets.

Trial Details: Testing Safety and Efficacy in 12 Patients

The trial specifics are as follows:

  • Target condition: Limbal stem cell deficiency (LSCD) — a condition where the stem cells that regenerate the corneal surface are lost due to injury or disease, causing the cornea to become opaque and vision to deteriorate severely
  • Trial sites: Osaka University Hospital and 5 additional facilities across Japan
  • Target enrollment: 12 patients
  • First transplant: Spring 2026
  • Estimated completion: December 2027
  • Next steps: Application for manufacturing and marketing approval after trial completion

Critically, this trial is classified as a "pivotal trial" — meaning it is designed to generate the definitive data needed for full regulatory approval. Reimei is aiming for full approval, not Japan's conditional and time-limited pathway. This distinction matters greatly in the international credibility of the results.

Already Proven: The Osaka University First-in-Human Study

This trial doesn't emerge from a vacuum. From 2019 onward, Professor Nishida's team at Osaka University conducted the world's first transplantation of iPS cell-derived corneal epithelial cell sheets. The results of this first-in-human study, involving four patients, were published in The Lancet — one of the world's top five medical journals — in November 2024.

The outcomes were remarkably encouraging. All four patients showed no tumor formation and no immune rejection. Every patient experienced reduced corneal clouding and improved vision. In the most striking case, corrected visual acuity recovered from 0.15 to 0.7, a level that meets Japan's standard for a driver's license (comparable to approximately 20/30 in the US measurement system).

Backed by Rohto Pharmaceutical: From Lab to Mass Production

To support the clinical trial and future commercialization, Reimei has received additional investment from Rohto Pharmaceutical Co., Ltd., one of Japan's largest eye care companies (known internationally for Rohto eye drops and skincare products).

This partnership is strategic on multiple levels. Rohto brings manufacturing expertise, distribution networks, and a deep understanding of the ophthalmology market. Meanwhile, the cryopreservable nature of REM-01 gives it a significant logistical advantage over traditional donor corneas, which have a limited shelf life.

Japan vs. the US: How Regenerative Medicine Gets Approved

Japan and the United States take notably different approaches to bringing regenerative therapies to market. Understanding these differences provides important context for why Japan is leading in this field.

Japan's PMDA (Pharmaceuticals and Medical Devices Agency): Japan introduced the world's first fast-track system specifically designed for regenerative medicine in 2014 — the "Conditional and Time-Limited Approval" pathway. Under this system, regenerative products can receive market approval for up to 7 years based on preliminary safety and efficacy data, with full approval contingent on additional post-market evidence. Japan also offers the Sakigake ("Pioneer") Designation, which accelerates review for innovative therapies first developed in Japan.

The US FDA (Food and Drug Administration): In 2017, three years after Japan, the FDA introduced its own accelerated pathway called the RMAT (Regenerative Medicine Advanced Therapy) designation, which was partly inspired by Japan's conditional approval system. RMAT designation expedites development and review of regenerative therapies for serious conditions, but the FDA generally requires larger clinical datasets before granting approval.

Japan's conditional approval system has also faced scrutiny. In 2024, Terumo Corporation's "HeartSheet" (an autologous skeletal myoblast sheet for heart failure) became the first product to lose its conditional approval after failing to demonstrate efficacy in post-market studies. This outcome actually demonstrated that Japan's system has teeth — conditional approval is not a rubber stamp, but a genuine trial period with real consequences.

Reimei's decision to design REM-01's trial as a pivotal study aiming for full approval, rather than relying on the conditional pathway, signals confidence in their product and addresses international concerns about the rigor of Japan's regulatory framework.

The Big Picture: iPS Cells in Eye Medicine

The eye has emerged as the leading frontier for iPS cell-based regenerative medicine, with Japan consistently at the forefront:

  • 2014: Dr. Masayo Takahashi (then at RIKEN, now CEO of Vision Care Inc.) performed the world's first iPS cell clinical procedure — transplanting retinal pigment epithelial cells for age-related macular degeneration
  • 2019: Professor Nishida's Osaka University team conducted the world's first iPS cell-derived corneal epithelial cell sheet transplantation
  • 2023: Japan approved Vyznova, a regenerative therapy product for corneal endothelial disease
  • 2026: Reimei launches the world's first corporate clinical trial of allogeneic iPS-derived corneal cell sheets

The eye is ideally suited for regenerative medicine: it requires relatively small amounts of tissue, transplanted cells can be monitored non-invasively, and the eye enjoys a degree of "immune privilege" that reduces the risk of rejection.

Will This Reach Patients Who Need It Most?

Even if the trial succeeds, one major question remains: affordability. iPS cell-derived products are expensive to manufacture, and the populations most affected by corneal blindness are in low- and middle-income countries where advanced therapies may be out of reach.

However, the allogeneic approach offers genuine hope for scale. Because the cell sheets can be manufactured in advance and cryopreserved, economies of scale become achievable as production ramps up. The Rohto partnership adds further credibility to the commercialization pathway.

The estimated cost per treatment has not been publicly disclosed, but Japan's national health insurance system — which covers approved regenerative medicine products — could provide a model for other countries to follow in making advanced therapies accessible.

What This Means for the World

Reimei's clinical trial represents a landmark moment in regenerative medicine. It is the culmination of two decades of research since Shinya Yamanaka first created iPS cells in 2006, plus decades more of Professor Nishida's corneal research at Osaka University.

If successful, REM-01 could fundamentally change how corneal blindness is treated worldwide: from depending on the generosity of deceased donors to manufacturing sight-restoring tissue on demand.

In Japan, people are debating the promise and the challenges — from excitement about scientific breakthroughs to concerns about long-term safety, cost, and equitable access. What about in your country? How is corneal disease treated? What are your thoughts on growing replacement body parts from stem cells? We'd love to hear your perspective in the comments.

References